Browsing Genetics and Epidemiology by author "Kaiser, Martin"
Now showing items 1-20 of 40
-
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto, P; Engelhardt, M; Caers, J; Bolli, N; Kaiser, M; et al. (FERRATA STORTI FOUNDATION, 2021-11-01)According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration ... -
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.
Hoang, PH; Cornish, AJ; Sherborne, AL; Chubb, D; Kimber, S; et al. (SPRINGERNATURE, 2020-10-14)Most patients with multiple myeloma (MM) die from progressive disease after relapse. To advance our understanding of MM evolution mechanisms, we performed whole-genome sequencing of 80 IGH-translocated tumour-normal newly ... -
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.
Went, M; Sud, A; Law, PJ; Johnson, DC; Weinhold, N; et al. (NATURE PUBLISHING GROUP, 2017-06-16) -
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Yong, KL; Hinsley, S; Auner, HW; Bygrave, C; Kaiser, MF; et al. (FERRATA STORTI FOUNDATION, 2021-10-01)The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these proteasome inhibitors in combination ... -
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Weinhold, N; Salwender, HJ; Cairns, DA; Raab, MS; Waldron, G; et al. (FERRATA STORTI FOUNDATION, 2021-10-01)Not available. -
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
Shah, V; Boyd, KD; Houlston, RS; Kaiser, MF (BMC, 2017-11-06)BACKGROUND: Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally ... -
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Croft, J; Ellis, S; Sherborne, AL; Sharp, K; Price, A; et al. (SPRINGERNATURE, 2020-12-01)Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. To investigate ... -
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser, MF; Hall, A; Walker, K; Sherborne, A; De Tute, RM; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-08-10)PURPOSE: The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) before and after autologous stem-cell transplant (ASCT) ... -
Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study.
Satchwell, L; Wedlake, L; Greenlay, E; Li, X; Messiou, C; et al. (BMJ PUBLISHING GROUP, 2022-10-05)INTRODUCTION: Whole-body MRI (WB-MRI) is recommended by the National Institute of Clinical Excellence as the first-line imaging tool for diagnosis of multiple myeloma. Reporting WB-MRI scans requires expertise to interpret ... -
Exploiting gene dependency to inform drug development for multiple myeloma.
Went, M; Hoang, PH; Law, PJ; Kaiser, MF; Houlston, RS (NATURE PORTFOLIO, 2022-07-26)Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for ... -
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani, SZ; Nahi, H; Legiec, W; Grosicki, S; Vorobyev, V; et al. (FERRATA STORTI FOUNDATION, 2022-10-01)In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma ... -
Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Ajore, R; Niroula, A; Pertesi, M; Cafaro, C; Thodberg, M; et al. (NATURE PORTFOLIO, 2022-01-10)Thousands of non-coding variants have been associated with increased risk of human diseases, yet the causal variants and their mechanisms-of-action remain obscure. In an integrative study combining massively parallel ... -
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.
Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; et al. (NATURE PUBLISHING GROUP, 2018-12-21)The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ... -
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; et al. (CELL PRESS, 2017-09-12)Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ... -
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
Law, PJ; Sud, A; Mitchell, JS; Henrion, M; Orlando, G; et al. (NATURE PORTFOLIO, 2017-01-23)B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, ... -
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
Mitchell, JS; Li, N; Weinhold, N; Försti, A; Ali, M; et al. (NATURE PUBLISHING GROUP, 2016-07-01)Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power ... -
Germline variants at SOHLH2 influence multiple myeloma risk.
Duran-Lozano, L; Thorleifsson, G; Lopez de Lapuente Portilla, A; Niroula, A; Went, M; et al. (SPRINGERNATURE, 2021-04-19)Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a ... -
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; et al. (2018-09-13)Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ... -
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; et al. (NATURE PUBLISHING GROUP, 2018-09-13)Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ... -
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Faustini, SE; Hall, A; Brown, S; Roberts, S; Hill, H; et al. (WILEY, 2023-06-01)Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome ...